News
Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...
Sanofi's $470M Vigil Neuroscience, Inc. acquisition highlights VG-3927's potential in Alzheimer's. Click here to find out why ...
With the deal, Sanofi gains Blueprint’s portfolio of rare immunological disease treatments, including systemic mastocytosis ...
The investment includes a significant boost to research and development and the expansion of partnerships with domestic ...
The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost ...
Sanofi paid $55 million to partner with the biotech in 2019 and handed over a further $22 million to expand the collaboration ...
The new version of Sarclisa stems from a collaboration with Enable Injections, backed financially to the tune of €300 million ...
Global Employee Stock Purchase Plan . Paris, June 5, 2025. Sanofi's global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 em ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback